Our work suggests that TAGLN2, YBX1 and induced ISGs are novel predictive markers for clinical outcomes, and that targeting TAGLN2-mediated ISG upregulation is an attractive therapeutic sensitization strategy for gastric cancer patients. Here, TAGLN2 is linked to gastric cancer.